PATENT CLAIM ANALYSIS

Application Number: 16002948
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-05
Patent Classification: ["514", "279000"]

Abstract:
Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Claim (Index 3):
Rifaximin in polymorphic form \u03b3.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 94.0
- Lexical Diversity: 1.69841
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13041332', '13041346', '12119600', '12478638', '12119612']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7676680319276387
- 35 USC 102 Novelty (BERT): 0.5288586009837981
- Combined Prediction Score: 0.7437870888332546
- Mean Citation Score: 298.821826
- Max Citation Score: 308.543
- Similarity Product: 198.88127425646783

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test